1. Home
  2. TROX vs TVTX Comparison

TROX vs TVTX Comparison

Compare TROX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TROX
  • TVTX
  • Stock Information
  • Founded
  • TROX 2018
  • TVTX 2008
  • Country
  • TROX United States
  • TVTX United States
  • Employees
  • TROX N/A
  • TVTX N/A
  • Industry
  • TROX Major Chemicals
  • TVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TROX Industrials
  • TVTX Health Care
  • Exchange
  • TROX Nasdaq
  • TVTX Nasdaq
  • Market Cap
  • TROX N/A
  • TVTX 1.7B
  • IPO Year
  • TROX 2005
  • TVTX N/A
  • Fundamental
  • Price
  • TROX $5.12
  • TVTX $20.44
  • Analyst Decision
  • TROX Buy
  • TVTX Strong Buy
  • Analyst Count
  • TROX 7
  • TVTX 14
  • Target Price
  • TROX $9.64
  • TVTX $33.31
  • AVG Volume (30 Days)
  • TROX 3.1M
  • TVTX 1.6M
  • Earning Date
  • TROX 04-30-2025
  • TVTX 05-01-2025
  • Dividend Yield
  • TROX 9.42%
  • TVTX N/A
  • EPS Growth
  • TROX N/A
  • TVTX N/A
  • EPS
  • TROX N/A
  • TVTX N/A
  • Revenue
  • TROX $3,038,000,000.00
  • TVTX $273,533,000.00
  • Revenue This Year
  • TROX $4.39
  • TVTX $68.31
  • Revenue Next Year
  • TROX $5.39
  • TVTX $55.65
  • P/E Ratio
  • TROX N/A
  • TVTX N/A
  • Revenue Growth
  • TROX 4.18
  • TVTX 75.65
  • 52 Week Low
  • TROX $4.35
  • TVTX $6.01
  • 52 Week High
  • TROX $20.70
  • TVTX $25.29
  • Technical
  • Relative Strength Index (RSI)
  • TROX 39.99
  • TVTX 61.49
  • Support Level
  • TROX $4.82
  • TVTX $19.84
  • Resistance Level
  • TROX $5.93
  • TVTX $22.07
  • Average True Range (ATR)
  • TROX 0.32
  • TVTX 1.11
  • MACD
  • TROX 0.04
  • TVTX 0.42
  • Stochastic Oscillator
  • TROX 26.79
  • TVTX 77.85

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Share on Social Networks: